Angelman Syndrome (AS) - Market Insights, Epidemiology and Market Forecast 2028

Angelman Syndrome (AS) - Market Insights, Epidemiology and Market Forecast 2028

  • Pages: 100
  • Geography: Global
  • Delivery Timeline: 7-10 Business Days
  • Publication: Aug, 2019
  • SKU: DIMI0351
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's "Angelman Syndrome (AS) - Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.
Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan
Study Period: 2016-2028
Angelman Syndrome Understanding and Treatment Algorithm
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Angelman Syndrome  in the US, Europe, and Japan are also provided in the report.
Angelman Syndrome Epidemiology
This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.
Angelman Syndrome Product Profiles & Analysis
This part of the Angelman Syndrome report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.
Angelman Syndrome Market Outlook
The Angelman Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.
 
Angelman Syndrome Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.
Angelman Syndrome Report Insights

• Patient Population in Angelman Syndrome

• Therapeutic Approaches in Angelman Syndrome

• Angelman Syndrome Pipeline Analysis

• Angelman Syndrome Market Size and Trends

• Angelman Syndrome Market Opportunities

• Impact of upcoming Therapies in Angelman Syndrome
Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology
Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition Angelman Syndrome Report Assessment

• Current Treatment Practices in Angelman Syndrome 

• Unmet Needs in Angelman Syndrome 

• Detailed Angelman Syndrome Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers
Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Angelman Syndrome market

• Organize sales and marketing efforts by identifying the best opportunities for Angelman Syndrome market

• To understand the future market competition in the Angelman Syndrome market.

Table of Contents:

1. Report Introduction

2. Angelman Syndrome Market Overview at a Glance

2.1. Market Share Distribution of Angelman Syndrome in 2017

2.2. Market Share Distribution of Angelman Syndrome in 2028

3. Disease Background and Overview: Angelman Syndrome  

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Angelman Syndrome in 7MM

4.3. Total Prevalent Patient Population of Angelman Syndrome in 7MM – By Countries

5. Epidemiology of Angelman Syndrome by Countries

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Angelman Syndrome  

5.1.3. Sub-Type Specific cases of the Angelman Syndrome *

5.1.4. Sex- Specific Cases of the Angelman Syndrome *

5.1.5. Diagnosed Cases of the Angelman Syndrome  

5.1.6. Treatable Cases of the Angelman Syndrome  

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Angelman Syndrome  

5.4.3. Sub-Type Specific cases of the Angelman Syndrome *

5.4.4. Sex- Specific Cases of the Angelman Syndrome *

5.4.5. Diagnosed Cases of the Angelman Syndrome  

5.4.6. Treatable Cases of the Angelman Syndrome  

5.5. France

5.5.1. Assumptions and Rationale

5.5.2. Prevalent/Incident Cases of the Angelman Syndrome  

5.5.3. Sub-Type Specific cases of the Angelman Syndrome *

5.5.4. Sex- Specific Cases of the Angelman Syndrome *

5.5.5. Diagnosed Cases of the Angelman Syndrome  

5.5.6. Treatable Cases of the Angelman Syndrome  

5.6. Italy

5.6.1. Assumptions and Rationale

5.6.2. Prevalent/Incident Cases of the Angelman Syndrome  

5.6.3. Sub-Type Specific cases of the Angelman Syndrome *

5.6.4. Sex- Specific Cases of the Angelman Syndrome *

5.6.5. Diagnosed Cases of the Angelman Syndrome  

5.6.6. Treatable Cases of the Angelman Syndrome  

5.7. Spain

5.7.1. Assumptions and Rationale

5.7.2. Prevalent/Incident Cases of the Angelman Syndrome  

5.7.3. Sub-Type Specific cases of the Angelman Syndrome *

5.7.4. Sex- Specific Cases of the Angelman Syndrome *

5.7.5. Diagnosed Cases of the Angelman Syndrome  

5.7.6. Treatable Cases of the Angelman Syndrome  

5.8. United Kingdom

5.8.1. Assumptions and Rationale

5.8.2. Prevalent/Incident Cases of the Angelman Syndrome  

5.8.3. Sub-Type Specific cases of the Angelman Syndrome *

5.8.4. Sex- Specific Cases of the Angelman Syndrome *

5.8.5. Diagnosed Cases of the Angelman Syndrome  

5.8.6. Treatable Cases of the Angelman Syndrome  

5.9. Japan

5.9.1. Assumptions and Rationale

5.9.2. Prevalent/Incident Cases of the Angelman Syndrome  

5.9.3. Sub-Type Specific cases of the Angelman Syndrome *

5.9.4. Sex- Specific Cases of the Angelman Syndrome *

5.9.5. Diagnosed Cases of the Angelman Syndrome  

5.9.6. Treatable Cases of the Angelman Syndrome  

6. Current Treatment & Medical practices

6.1. Treatment Algorithm

6.2. Treatment Guidelines

7. Unmet Needs of the Angelman Syndrome  

8. Marketed Therapies

8.1. Drug A: Company 1

8.1.1. Drug Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Advantages & Disadvantages

8.1.5. Product Profile

8.2. Drug B: Company 2

8.2.1. Drug Description

8.2.2. Mechanism of Action

8.2.3. Regulatory Milestones

8.2.4. Advantages & Disadvantages

8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Angelman Syndrome  

11.1. Drug C: Company 3

11.1.1. Drug Description

11.1.2. Clinical Trials Details

11.1.3. Safety and Efficacy Profile

11.1.4. Advantages & Disadvantages

11.1.5. Pipeline Development Activities

11.1.6. Product Profile

11.2. Drug D: Company 4

11.2.1. Drug Description

11.2.2. Clinical Trials Details

11.2.3. Safety and Efficacy Profile

11.2.4. Advantages & Disadvantages

11.2.5. Pipeline Development Activities

11.2.6. Product Profile

12. Angelman Syndrome: 7MM Market Analysis

12.1. 7MM Market Size of Angelman Syndrome  

12.2. 7MM Percentage Share of drugs marketed for Angelman Syndrome  

12.3. 7MM Market Sales of Angelman Syndrome by Products

13. Angelman Syndrome: Country-Wise Market Analysis

13.1. United States

13.1.1. Market Size of Angelman Syndrome in United States

13.1.2. Percentage Share of drugs marketed for Angelman Syndrome in United States

13.1.3. Market Sales of Angelman Syndrome by Products in United States

13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2. EU-5

13.2.1. Germany

13.2.1.1. Market Size of Angelman Syndrome in Germany

13.2.1.2. Percentage Share of drugs marketed for Angelman Syndrome in Germany

13.2.1.3. Market Sales of Angelman Syndrome by Products in Germany

13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.2. France

13.2.2.1. Market Size of Angelman Syndrome in France

13.2.2.2. Percentage Share of drugs marketed for Angelman Syndrome in France

13.2.2.3. Market Sales of Angelman Syndrome by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Angelman Syndrome in Italy

13.2.3.2. Percentage Share of drugs marketed for Angelman Syndrome in Italy

13.2.3.3. Market Sales of Angelman Syndrome by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Angelman Syndrome in Spain

13.2.4.2. Percentage Share of drugs marketed for Angelman Syndrome in Spain

13.2.4.3. Market Sales of Angelman Syndrome by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Angelman Syndrome in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Angelman Syndrome in United Kingdom

13.2.5.3. Market Sales of Angelman Syndrome by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Angelman Syndrome in Japan

13.3.2. Percentage Share of drugs marketed for Angelman Syndrome in Japan

13.3.3. Market Sales of Angelman Syndrome by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Table 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Table 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Table 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Table 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Table 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Table 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Table 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Table 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Table 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Table 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Table 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Figure 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Figure 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Figure 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Figure 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Figure 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Figure 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 22: Treatable Cases of the Angelman Syndrome in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Angelman Syndrome in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 27: Treatable Cases of the Angelman Syndrome in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Angelman Syndrome in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Angelman Syndrome in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Angelman Syndrome in UK (2016-2028)

Figure 31: Diagnosed Cases of the Angelman Syndrome in UK (2016-2028)

Figure 32: Treatable Cases of the Angelman Syndrome in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Angelman Syndrome in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 37: Treatable Cases of the Angelman Syndrome in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 42:7MM- Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 45: United States-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 48: Germany-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 51: France-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 54: Italy-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 57: Spain-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Angelman Syndrome  in USD MM (2016-2028)

Figure 60:UK-Market Share Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Angelman Syndrome  by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Angelman Syndrome in USD MM (2016-2028)

Figure 63: Japan-Market Share Angelman Syndrome by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Angelman Syndrome by Therapies in USD MM (2016-2028)

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM

Table 2: Total Prevalent/Incident Cases of the Angelman Syndrome in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Angelman Syndrome in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Angelman Syndrome in United States (2016-2028)

Table 5: Sex- Specific Cases of the Angelman Syndrome in United States (2016-2028)

Table 6: Diagnosed Cases of the Angelman Syndrome in United States (2016-2028)

Table 7: Treatable Cases of the Angelman Syndrome in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Angelman Syndrome in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Angelman Syndrome in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Angelman Syndrome in Germany (2016-2028)

Table 11: Diagnosed Cases of the Angelman Syndrome in Germany (2016-2028)

Table 12: Treatable Cases of the Angelman Syndrome in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Angelman Syndrome in France (2016-2028)

Table 14: Sub-Type Specific cases of the Angelman Syndrome in France (2016-2028)

Table 15: Sex- Specific Cases of the Angelman Syndrome in France (2016-2028)

Table 16: Diagnosed Cases of the Angelman Syndrome in France (2016-2028)

Table 17: Treatable Cases of the Angelman Syndrome in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Angelman Syndrome in Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Angelman Syndrome in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Angelman Syndrome in I